76 related articles for article (PubMed ID: 18362666)
1. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in High-Risk Corneal Transplantation: A Pilot Multicenter Prospective Randomized Control Trial.
Dohlman TH; McSoley M; Amparo F; Carreno-Galeano T; Wang M; Dastjerdi M; Singh RB; Coco G; Di Zazzo A; Shikari H; Saboo U; Sippel K; Ciralsky J; Yoo SH; Sticca M; Wakamatsu TH; Murthy S; Hamrah P; Jurkunas U; Ciolino JB; Gomes JAP; Perez VL; Yin J; Dana R
Ophthalmology; 2022 Aug; 129(8):865-879. PubMed ID: 35358592
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic effect of a humanized antibody blocking the Wnt/β-catenin signaling pathway.
Qiu F; Shin Y; Chen D; Cheng R; Chen Q; Zhou K; Larrick JW; Mendelson AR; Ma JX
Microvasc Res; 2018 Sep; 119():29-37. PubMed ID: 29630973
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of fumagillin bicyclohexylamine on experimental corneal neovascularization in rat model.
Aşula MF; Onur IU; Yigit FU
Int Ophthalmol; 2019 Jul; 39(7):1553-1558. PubMed ID: 30006905
[TBL] [Abstract][Full Text] [Related]
5. Effect of topical motesanib in experimental corneal neovascularization model.
Çelenk M; Yıldırım H; Tektemur A; Balbaba M; Erdağ M
Int Ophthalmol; 2023 Aug; 43(8):2989-2997. PubMed ID: 36971928
[TBL] [Abstract][Full Text] [Related]
6. [A randomized study of subconjonctival bevacizumab (Avastin®) injection for corneal neovascularization].
Rocher M; Benayoun Y; Quilbe S; Laribi S; Fournie P; Leveziel N; Trone MC; Bourcier T; Robert PY
J Fr Ophtalmol; 2024 Apr; 47(5):104152. PubMed ID: 38696862
[TBL] [Abstract][Full Text] [Related]
7. Comparison of photodynamic therapy with two different parameters combined with subconjunctival injection of bevacizumab for corneal neovascularization.
Yin XF; Wu MH; Jin CJ; Zhou SY
Photodiagnosis Photodyn Ther; 2024 Apr; 46():104067. PubMed ID: 38548042
[TBL] [Abstract][Full Text] [Related]
8. Topical axitinib is a potent inhibitor of corneal neovascularization.
Lledó Riquelme M; Campos-Mollo E; Fernández-Sánchez L
Clin Exp Ophthalmol; 2018 Dec; 46(9):1063-1074. PubMed ID: 29888852
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory Effect of Topical Cartilage Acellular Matrix Suspension Treatment on Neovascularization in a Rabbit Corneal Model.
Yun HW; Choi BH; Park DY; Jin LH; Min BH
Tissue Eng Regen Med; 2020 Oct; 17(5):625-640. PubMed ID: 32617955
[TBL] [Abstract][Full Text] [Related]
10. Reply: To PMID 22967868.
Cheng SF; Dastjerdi MH; Ferrari G; Okanobo A; Amparo F; Stevenson W; Hamrah P; Nallasamy N; Dana R; Bower KS; Ryan DS
Am J Ophthalmol; 2013 Jul; 156(1):204-5. PubMed ID: 23791375
[No Abstract] [Full Text] [Related]
11. Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization.
Chen WL; Chen YM; Chu HS; Lin CT; Chow LP; Chen CT; Hu FR
PLoS One; 2014; 9(4):e94205. PubMed ID: 24714670
[TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF therapy with bevacizumab for anterior segment eye disease.
Hosseini H; Nowroozzadeh MH; Salouti R; Nejabat M
Cornea; 2012 Mar; 31(3):322-34. PubMed ID: 22157572
[TBL] [Abstract][Full Text] [Related]
13. Steroid-eluting contact lenses for corneal and intraocular inflammation.
Bengani LC; Kobashi H; Ross AE; Zhai H; Salvador-Culla B; Tulsan R; Kolovou PE; Mittal SK; Chauhan SK; Kohane DS; Ciolino JB
Acta Biomater; 2020 Oct; 116():149-161. PubMed ID: 32814140
[TBL] [Abstract][Full Text] [Related]
14. The Antiangiogenic Properties of Adipose-Derived Mesenchymal Stem/Stromal Cells in Corneal Neovascularization in a Rabbit Model.
Pirounides D; Komnenou A; Papaioannou N; Gounari E; Stylianaki I; Alexandridis A; Chranioti A; Kofidou E; Koliakos G; Karampatakis V
Med Hypothesis Discov Innov Ophthalmol; 2020; 9(2):74-84. PubMed ID: 32490014
[TBL] [Abstract][Full Text] [Related]
15. Local delivery of corticosteroids in clinical ophthalmology: A review.
Fung AT; Tran T; Lim LL; Samarawickrama C; Arnold J; Gillies M; Catt C; Mitchell L; Symons A; Buttery R; Cottee L; Tumuluri K; Beaumont P
Clin Exp Ophthalmol; 2020 Apr; 48(3):366-401. PubMed ID: 31860766
[TBL] [Abstract][Full Text] [Related]
16. Intrastromal bevacizumab in the management of corneal neovascularization: a retrospective review.
Gupta AA; Mammo DA; Page MA
Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):167-173. PubMed ID: 31713747
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the inhibitory effect of different doses of subconjunctival bevacizumab application in an experimental model of corneal neovascularization.
Ulas B; Altan-Yaycioglu R; Bal N
Int J Ophthalmol; 2018; 11(7):1090-1095. PubMed ID: 30046522
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging therapies for corneal neovascularization.
Roshandel D; Eslani M; Baradaran-Rafii A; Cheung AY; Kurji K; Jabbehdari S; Maiz A; Jalali S; Djalilian AR; Holland EJ
Ocul Surf; 2018 Oct; 16(4):398-414. PubMed ID: 29908870
[TBL] [Abstract][Full Text] [Related]
19. Topical Timolol Inhibits Corneal Neovascularization in Rabbits.
Kasiri A; Ghomi MR; Feghhi M; Farrahi F; Mirdehghan MS; Hedayati H
Med Hypothesis Discov Innov Ophthalmol; 2017; 6(2):39-43. PubMed ID: 29367933
[TBL] [Abstract][Full Text] [Related]
20. Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats.
Hashemian MN; Mahrjerdi HZ; Mazloumi M; Safizadeh MS; Shakiba Y; Rahimi F; Afarideh M; Zare MA; Tafti MF; Sepidan BB; Abtahi MA; Abtahi SH
J Res Med Sci; 2017; 22():16. PubMed ID: 28458707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
